{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:09:33Z","timestamp":1776348573685,"version":"3.51.2"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007652","name":"Instituto Nacional de Investigaci\u00f3n y Tecnolog\u00eda Agraria y Alimentaria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007652","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["AGL2017-82570-R"],"award-info":[{"award-number":["AGL2017-82570-R"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.coviro.2020.06.003","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T18:11:39Z","timestamp":1594404699000},"page":"49-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design"],"prefix":"10.1016","volume":"44","author":[{"given":"Eva","family":"Calvo-Pinilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Mar\u00edn-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Utrilla-Trigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds","family":"Jim\u00e9nez-Cabello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Ortego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2020.06.003_bib0005","first-page":"7","article-title":"The transmission of bluetongue and horse sickness by Culicoides","volume":"19","author":"Du Toit","year":"1944","journal-title":"Onderstepoort J Vet Sci Anim Ind"},{"key":"10.1016\/j.coviro.2020.06.003_bib0010","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev-ento-031616-035010","article-title":"African horse sickness virus: history, transmission, and current status","volume":"62","author":"Carpenter","year":"2017","journal-title":"Annu Rev Entomol"},{"key":"10.1016\/j.coviro.2020.06.003_bib0015","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1051\/vetres:2004021","article-title":"African horse sickness","volume":"35","author":"Mellor","year":"2004","journal-title":"Vet Res"},{"key":"10.1016\/j.coviro.2020.06.003_bib0020","first-page":"139","article-title":"The isolation and identification of further antigenic types of African horsesickness virus","volume":"29","author":"Howell","year":"1962","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.coviro.2020.06.003_bib0025","first-page":"465","article-title":"Immunological types of horse sickness and their significance in immunization","volume":"27","author":"McIntosh","year":"1958","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.coviro.2020.06.003_bib0030","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0147-9571(94)90046-9","article-title":"African horse sickness virus structure","volume":"17","author":"Roy","year":"1994","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.coviro.2020.06.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124281","article-title":"Characterising non-structural protein NS4 of African horse sickness virus","volume":"10","author":"Zwart","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2020.06.003_bib0040","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/vir.0.83502-0","article-title":"Molecular epidemiology of the African horse sickness virus S10 gene","volume":"89","author":"Quan","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2020.06.003_bib0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/tbed.12024","article-title":"African horse sickness outbreaks caused by multiple virus types in Ethiopia","volume":"61","author":"Aklilu","year":"2014","journal-title":"Transbound Emerg Dis"},{"key":"10.1016\/j.coviro.2020.06.003_bib0050","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/vr.e292","article-title":"Schmallenberg virus: a novel viral disease in northern Europe","volume":"170","author":"Gibbens","year":"2012","journal-title":"Vet Rec"},{"key":"10.1016\/j.coviro.2020.06.003_bib0055","doi-asserted-by":"crossref","first-page":"427","DOI":"10.20506\/rst.27.2.1801","article-title":"Invasion of bluetongue and other orbivirus infections into Europe: the role of biological and climatic processes","volume":"27","author":"Purse","year":"2008","journal-title":"Rev Sci Tech"},{"key":"10.1016\/j.coviro.2020.06.003_bib0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1017\/S0950268899002897","article-title":"African horse sickness in Portugal: a successful eradication programme","volume":"123","author":"Portas","year":"1999","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.coviro.2020.06.003_bib0065","series-title":"Infectious Diseases of Livestock","first-page":"1231","article-title":"African horse sickness","author":"Coetzer","year":"2004"},{"key":"10.1016\/j.coviro.2020.06.003_bib0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.2042-3306.2012.00590.x","article-title":"African horse sickness in naturally infected, immunised horses","volume":"45","author":"Weyer","year":"2012","journal-title":"Equine Vet J"},{"key":"10.1016\/j.coviro.2020.06.003_bib0075","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3201\/eid2212.160718","article-title":"African horse sickness caused by genome reassortment and reversion to virulence of live, attenuated vaccine viruses, South Africa, 2004-2014","volume":"22","author":"Weyer","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2020.06.003_bib0080","first-page":"463","article-title":"Vaccination in the control of bluetongue in endemic regions: the South African experience","volume":"119","author":"Dungu","year":"2004","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.coviro.2020.06.003_bib0085","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1016\/j.vaccine.2010.06.105","article-title":"In vivo cross-protection to African horse sickness serotypes 5 and 9 after vaccination with serotypes 8 and 6","volume":"28","author":"von Teichman","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.06.003_bib0090","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1016\/j.vaccine.2008.07.037","article-title":"Evaluation of the pathogenicity of African horsesickness (AHS) isolates in vaccinated animals","volume":"26","author":"von Teichman","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.06.003_bib0095","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.vetimm.2012.06.009","article-title":"An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses","volume":"149","author":"El Garch","year":"2012","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.coviro.2020.06.003_bib0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016503","article-title":"A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -\/- mouse model","volume":"6","author":"Castillo-Olivares","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2020.06.003_bib0105","doi-asserted-by":"crossref","first-page":"e5997","DOI":"10.1371\/journal.pone.0005997","article-title":"Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA)","volume":"4","author":"Chiam","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2020.06.003_bib0110","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1016\/j.vaccine.2014.04.036","article-title":"Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge","volume":"32","author":"Alberca","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.06.003_bib0115","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1016\/j.vaccine.2018.09.065","article-title":"A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model","volume":"36","author":"Aksular","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.06.003_bib0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070197","article-title":"Ns1 is a key protein in the vaccine composition to protect Ifnar(-\/-) mice against infection with multiple serotypes of African horse sickness virus","volume":"8","author":"de la Poza","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2020.06.003_bib0125","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1749-6632.1996.tb53539.x","article-title":"Multiple gene expression in baculovirus system. Third generation vaccines for bluetongue disease and African horsesickness disease","volume":"791","author":"Roy","year":"1996","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.coviro.2020.06.003_bib0130","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1099\/0022-1317-77-9-2053","article-title":"Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge","volume":"77","author":"Roy","year":"1996","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2020.06.003_bib0135","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1016\/j.vaccine.2017.04.005","article-title":"Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination","volume":"35","author":"Manning","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.06.003_sbref0140","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.vaccine.2018.03.003","article-title":"African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3\/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform","volume":"36","author":"van Rijn","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.06.003_sbref0145","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1016\/j.vaccine.2017.06.023","article-title":"Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge","volume":"35","author":"Lulla","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.06.003_bib0150","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1016\/j.vaccine.2009.05.044","article-title":"Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus","volume":"27","author":"Guthrie","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.06.003_bib0155","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1099\/0022-1317-77-6-1211","article-title":"Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7","volume":"77","author":"Martinez-Torrecuadrada","year":"1996","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2020.06.003_bib0160","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1016\/j.vaccine.2014.07.031","article-title":"Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus","volume":"32","author":"Kanai","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.06.003_bib0165","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13567-018-0600-4","article-title":"Safety and immunogenicity of plant-produced African horse sickness virus-like particles in horses","volume":"49","author":"Dennis","year":"2018","journal-title":"Vet Res"},{"key":"10.1016\/j.coviro.2020.06.003_bib0170","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s12917-019-2184-2","article-title":"Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness","volume":"15","author":"Rutkowska","year":"2019","journal-title":"BMC Vet Res"},{"key":"10.1016\/j.coviro.2020.06.003_bib0175","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.virusres.2015.12.006","article-title":"Synthesis of empty African horse sickness virus particles","volume":"213","author":"Maree","year":"2016","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2020.06.003_bib0180","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/pbi.12783","article-title":"Immunogenicity of plant-produced African horse sickness virus-like particles: implications for a novel vaccine","volume":"16","author":"Dennis","year":"2018","journal-title":"Plant Biotechnol J"},{"key":"10.1016\/j.coviro.2020.06.003_sbref0185","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.vaccine.2019.10.087","article-title":"Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara","volume":"38","author":"Marin-Lopez","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.06.003_bib0190","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1006\/viro.1993.1537","article-title":"Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2","volume":"196","author":"Burrage","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2020.06.003_bib0195","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1099\/0022-1317-81-4-993","article-title":"Identification of antigenic regions on VP2 of African horsesickness virus serotype 3 by using phage-displayed epitope libraries","volume":"81","author":"Bentley","year":"2000","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2020.06.003_bib0200","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2015.01.009","article-title":"Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge","volume":"116","author":"Calvo-Pinilla","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2020.06.003_bib0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virusres.2013.12.002","article-title":"Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation","volume":"180","author":"Calvo-Pinilla","year":"2014","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2020.06.003_bib0210","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2018.04.015","article-title":"The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host","volume":"154","author":"Calvo-Pinilla","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2020.06.003_sbref0215","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1016\/j.vaccine.2017.04.005","article-title":"Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination","volume":"35","author":"Manning","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2020.06.003_bib0220","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.virusres.2015.08.005","article-title":"Identification of CD8 T cell epitopes in VP2 and NS1 proteins of African horse sickness virus in IFNAR(-\/-) mice","volume":"210","author":"de la Poza","year":"2015","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2020.06.003_bib0225","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.6272391","article-title":"Cloned poliovirus complementary DNA is infectious in mammalian cells","volume":"214","author":"Racaniello","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.coviro.2020.06.003_bib0230","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3390\/v6072531","article-title":"RNA virus reverse genetics and vaccine design","volume":"6","author":"Stobart","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2020.06.003_bib0235","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.1128\/JVI.00808-08","article-title":"Development of reverse genetics systems for bluetongue virus: recovery of infectious virus from synthetic RNA transcripts","volume":"82","author":"Boyce","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.06.003_sbref0240","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.virol.2016.07.010","article-title":"Establishment of different plasmid only-based reverse genetics systems for the recovery of African horse sickness virus","volume":"499","author":"Conradie","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2020.06.003_bib0245","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1618424114","article-title":"Entirely plasmid-based reverse genetics system for rotaviruses","volume":"114","author":"Kanai","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2020.06.003_sbref0250","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1099\/vir.0.055905-0","article-title":"Recovery of African horse sickness virus from synthetic RNA","volume":"94","author":"Kaname","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2020.06.003_bib0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005455","article-title":"Reverse genetics for fusogenic bat-borne orthoreovirus associated with acute respiratory tract infections in humans: role of outer capsid protein sigmaC in viral replication and pathogenesis","volume":"12","author":"Kawagishi","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2020.06.003_bib0260","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.virol.2009.11.037","article-title":"An improved reverse genetics system for mammalian orthoreoviruses","volume":"398","author":"Kobayashi","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2020.06.003_bib0265","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.fob.2015.05.006","article-title":"Development of reverse genetics for Ibaraki virus to produce viable VP6-tagged IBAV","volume":"5","author":"Matsuo","year":"2015","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.coviro.2020.06.003_bib0270","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.virol.2015.09.004","article-title":"Establishment of an entirely plasmid-based reverse genetics system for bluetongue virus","volume":"486","author":"Pretorius","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2020.06.003_bib0275","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1099\/vir.0.000192","article-title":"Development of a reverse genetics system for epizootic hemorrhagic disease virus and evaluation of novel strains containing duplicative gene rearrangements","volume":"96","author":"Yang","year":"2015","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2020.06.003_sbref0280","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1016\/j.febslet.2010.06.030","article-title":"A reverse genetics system of African horse sickness virus reveals existence of primary replication","volume":"584","author":"Matsuo","year":"2010","journal-title":"FEBS Lett"},{"key":"10.1016\/j.coviro.2020.06.003_bib0285","doi-asserted-by":"crossref","first-page":"8842","DOI":"10.1128\/JVI.00465-09","article-title":"Bluetongue virus VP6 acts early in the replication cycle and can form the basis of chimeric virus formation","volume":"83","author":"Matsuo","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.06.003_sbref0290","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.1128\/JVI.00548-16","article-title":"Assembly of replication-incompetent African horse sickness virus particles: rational design of vaccines for all serotypes","volume":"90","author":"Lulla","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.06.003_bib0295","doi-asserted-by":"crossref","first-page":"8764","DOI":"10.1128\/JVI.01052-15","article-title":"VP2 exchange and NS3\/NS3a deletion in African Horse Sickness Virus (AHSV) in development of disabled infectious single animal vaccine candidates for AHSV","volume":"89","author":"van de Water","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.06.003_bib0300","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01328-16","article-title":"Structural protein VP2 of African horse sickness virus is not essential for virus replication in vitro","volume":"91","author":"van Gennip","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.06.003_bib0305","first-page":"366","article-title":"African horse sickness virus NS4 is a nucleocytoplasmic protein that localizes to PML nuclear bodies","volume":"101","author":"Boughan","year":"2020","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2020.06.003_bib0310","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00186-20","article-title":"A lassa virus live-attenuated vaccine candidate based on rearrangement of the intergenic region","volume":"11","author":"Cai","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2020.06.003_bib0315","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1128\/JVI.01565-14","article-title":"Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development","volume":"88","author":"Nogales","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.06.003_bib0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005215","article-title":"Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine","volume":"11","author":"Jimenez-Guardeno","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2020.06.003_bib0325","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1099\/vir.0.065615-0","article-title":"Bluetongue virus without NS3\/NS3a expression is not virulent and protects against virulent bluetongue virus challenge","volume":"95","author":"Feenstra","year":"2014","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2020.06.003_bib0330","doi-asserted-by":"crossref","first-page":"10213","DOI":"10.1128\/JVI.05412-11","article-title":"Generation of replication-defective virus-based vaccines that confer full protection in sheep against virulent bluetongue virus challenge","volume":"85","author":"Matsuo","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.06.003_bib0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002477","article-title":"Identification and characterization of a novel non-structural protein of bluetongue virus","volume":"7","author":"Ratinier","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2020.06.003_bib0340","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1128\/JVI.00422-16","article-title":"Bluetongue virus NS4 protein is an interferon antagonist and a determinant of virus virulence","volume":"90","author":"Ratinier","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2020.06.003_bib0345","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0264-410X(01)00445-5","article-title":"The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant","volume":"20","author":"Scanlen","year":"2002","journal-title":"Vaccine"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625720300353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625720300353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:02:46Z","timestamp":1761818566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625720300353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":69,"alternative-id":["S1879625720300353"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2020.06.003","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2020.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}